By Suherman Candra Maholtra 
In a significant advancement for global public health, researchers at the Massachusetts Institute of Technology (MIT) have developed a new type of vaccine delivery system that could eliminate the need for multiple clinic visits. By utilizing specialized microparticles that release their contents at precise intervals, this technology promises a "one-and-done" approach to childhood immunizations. The study, published in the journal Advanced Materials, details how these self-boosting vaccines could bridge the gap in healthcare access that currently leaves millions of children vulnerable to preventable diseases.
According to global health data, approximately 20 percent of children worldwide are not fully immunized. This gap in coverage results in an estimated 1.5 million deaths annually from diseases that are entirely preventable through existing vaccination protocols. A critical challenge identified by health organizations is the "dropout rate"—nearly half of underimmunized children receive their initial dose but fail to return for the necessary follow-up boosters. In many regions, particularly in the developing world and rural areas of the United States, the logistical hurdles of traveling to a medical facility multiple times over several months prove insurmountable for many families.
The Challenge of Multi-Dose Immunization Schedules
The current standard of care for many life-saving vaccines requires a primary dose followed by one or more boosters to achieve long-term immunity. For example, the DTaP vaccine (protecting against diphtheria, tetanus, and acellular pertussis) requires a series of five shots, while the polio vaccine typically involves four doses. Each required visit increases the risk that a child will fall behind the schedule due to economic constraints, lack of transportation, or limited healthcare infrastructure.
To address this, the MIT team, led by senior authors Ana Jaklenec and Robert Langer, focused on creating a delivery vehicle that can be injected once but function as multiple doses. The core of this innovation lies in microparticles that act like tiny, timed-release capsules. These particles are designed to remain dormant in the body for weeks or even months before suddenly rupturing and releasing their vaccine payload.
Evolution from PLGA to Polyanhydrides
The quest for a single-injection vaccine is not new. In 2018, the MIT group demonstrated a proof-of-concept using a polymer known as PLGA (poly lactic-co-glycolic acid). While PLGA is widely used in medical devices and drug delivery, the researchers encountered a significant hurdle: as PLGA degrades in the body, it produces acidic byproducts. This localized drop in pH can damage the delicate proteins and antigens within the vaccine, rendering the booster dose ineffective before it is even released.
Recognizing this limitation, the researchers turned their attention to polyanhydrides. These are biodegradable polymers that were originally developed by Robert Langer more than four decades ago for different drug delivery applications. Unlike PLGA, polyanhydrides are highly hydrophobic, meaning they repel water. As these polymers erode, they do not allow water to penetrate the interior as easily, and their breakdown products are significantly less acidic. This creates a much more stable environment for the vaccine "cargo."
Engineering the Microparticle: The SEAL Process
To create the delivery system, the researchers utilized a proprietary manufacturing technique known as Stamped Assembly of Polymer Layers, or SEAL. This process is akin to high-tech micro-molding. Using silicon molds, the team creates tiny, cup-shaped particles that are filled with the vaccine antigen. Once filled, a cap made of the same polyanhydride material is applied and fused to the cup using heat.
The engineering challenge was to find the perfect polymer recipe. Polyanhydrides are composed of monomer chains that can be configured in nearly endless combinations. For this study, the MIT team synthesized a library of 23 different polymers, varying the chemical structure and the ratio of monomers. They then subjected these materials to rigorous testing, ensuring they could withstand temperatures of 104 degrees Fahrenheit (40 degrees Celsius)—slightly above human body temperature—and remained stable during the manufacturing process.
Through this screening, the researchers eliminated brittle or poorly sealing materials, narrowing the field to six top candidates capable of precise, delayed release.
Integrating Machine Learning for Precision Delivery
One of the most innovative aspects of the MIT study was the integration of artificial intelligence to accelerate the development cycle. Predicting exactly when a polymer will degrade inside the human body is a complex task involving numerous variables, including molecular weight, monomer ratios, and the "loading capacity" of the particle.
The researchers developed a machine-learning model trained on their experimental data to predict the degradation timelines of nearly 500 different polymer variations. This computational approach allowed the team to bypass months of trial-and-error laboratory work. By inputting the desired release date, the model could suggest the specific polymer chemistry required to achieve that goal.
"Using this model, we can rapidly evaluate how different factors influence the release kinetics," noted Linzixuan (Rhoda) Zhang, the paper’s lead author and a recent PhD graduate in chemical engineering. The accuracy of the model was confirmed through tests in controlled buffers, proving that the team can now "program" vaccines to release after specific intervals.
Successful Animal Trials and Immune Response
To test the efficacy of the polyanhydride particles, the researchers conducted a study using mice. They designed a single-injection system for the diphtheria vaccine. One group of mice received a traditional schedule of two separate injections two weeks apart. Another group received a single injection containing both a "free" vaccine (for immediate release) and the microparticle-encapsulated vaccine (designed to release two weeks later).
The results were definitive. Four weeks after the initial injection, the mice that received the single-injection microparticle vaccine showed antibody levels comparable to those that had received two separate shots. This confirmed that the polyanhydride particles not only protected the vaccine from degradation but also successfully mimicked the biological effect of a traditional booster shot.
Broader Implications for Global Health and Medicine
The long-term goal of the Koch Institute researchers is to apply this technology to a wide array of childhood immunizations. If a child could receive their entire course of polio, measles, or hepatitis vaccines in a single visit, the 1.5 million annual deaths attributed to underimmunization could be drastically reduced.
"The long-term goal of this work is to develop vaccines that make immunization more accessible—especially for children living in areas where it’s difficult to reach health care facilities," said Ana Jaklenec. "This includes rural regions of the United States as well as parts of the developing world where infrastructure and medical clinics are limited."
Beyond childhood vaccines, the technology has potential applications in other areas of medicine:
- Oncology: Delivering immunotherapy agents that require sustained release to maintain an immune response against tumors.
- Chronic Disease Management: Providing long-term delivery of hormones or other biologics that currently require frequent injections.
- Global Pandemics: Streamlining mass vaccination campaigns where follow-up visits are logistically difficult to track.
Future Outlook and Challenges
While the results in mice are promising, the transition to human clinical trials will require further research. The MIT team is now looking to extend the release intervals to several months. Many childhood vaccines require boosters at the six-month or one-year mark. To achieve this, the researchers plan to experiment with increasing the molecular weight of the polymers or introducing cross-linking to further slow the degradation process.
Additionally, the technology must be tested with a variety of different antigens, including mRNA-based vaccines and live-attenuated viruses, to ensure that the polyanhydride environment remains protective across different vaccine platforms.
The study also highlights the importance of interdisciplinary collaboration, combining chemical engineering, materials science, and immunology. Supported in part by the National Cancer Institute, the project underscores how foundational research in polymer chemistry can lead to breakthroughs in infectious disease prevention.
As the world continues to grapple with the lessons of recent global health crises, the development of more resilient and accessible medical technologies remains a priority. The MIT microparticle system represents a paradigm shift in how we think about the "delivery" of health, moving toward a future where a single encounter with a healthcare provider can provide a lifetime of protection. By reducing the burden on both healthcare systems and families, this technology stands as a potent tool in the ongoing effort to ensure that no child dies from a preventable disease simply because they could not reach a clinic for a second dose.